Goldman Sachs Group Inc. Sells 3,971 Shares of Protara Therapeutics, Inc. $TARA

Goldman Sachs Group Inc. cut its holdings in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 2.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 199,254 shares of the company’s stock after selling 3,971 shares during the period. Goldman Sachs Group Inc.’s holdings in Protara Therapeutics were worth $849,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TARA. Bank of America Corp DE lifted its holdings in Protara Therapeutics by 53,013.9% during the fourth quarter. Bank of America Corp DE now owns 194,397 shares of the company’s stock worth $1,026,000 after acquiring an additional 194,031 shares in the last quarter. Millennium Management LLC lifted its holdings in Protara Therapeutics by 2,479.2% during the fourth quarter. Millennium Management LLC now owns 371,453 shares of the company’s stock worth $1,961,000 after acquiring an additional 357,051 shares in the last quarter. Squarepoint Ops LLC bought a new position in Protara Therapeutics during the fourth quarter worth about $110,000. Toronto Dominion Bank bought a new position in Protara Therapeutics during the fourth quarter worth about $11,030,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Protara Therapeutics during the first quarter worth about $64,000. 38.13% of the stock is currently owned by institutional investors.

Protara Therapeutics Trading Down 2.5%

TARA stock opened at $3.58 on Wednesday. The business’s 50-day moving average price is $3.18 and its two-hundred day moving average price is $3.43. The firm has a market cap of $138.12 million, a PE ratio of -2.21 and a beta of 1.52. Protara Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Monday, August 11th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. On average, analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.